⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ARQT News

Arcutis Biotherapeutics, Inc. Common Stock

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older